Prognostic classification of pediatric medulloblastoma based on chromosome 17p loss, expression of MYCC and MYCN, and Wnt pathway activation.
暂无分享,去创建一个
O. Delattre | W. Park | S. Puget | C. Sainte-Rose | J. Grill | F. Bourdeaut | K. Wang | B. Cho | Seung-Ki Kim | C. Dufour | A. Park | D. Kim | C. Haberler | J. Phi | Seung-Jun Lee | S. Fattet | Seung-Ki Kim
[1] J. Mesirov,et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Hendrik Witt,et al. Medulloblastoma comprises four distinct molecular variants. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Chae-Yong Kim,et al. Cerebrospinal fluid M staging for medulloblastoma: reappraisal of Chang's M staging based on the CSF flow. , 2011, Neuro-oncology.
[4] Yiai Tong,et al. Subtypes of medulloblastoma have distinct developmental origins , 2010, Nature.
[5] Eric C. Holland,et al. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma , 2010, Nature Reviews Cancer.
[6] J. Ross,et al. Multigene Classifiers, Prognostic Factors, and Predictors of Breast Cancer Clinical Outcome , 2009, Advances in anatomic pathology.
[7] Emmanuel Barillot,et al. Beta‐catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics , 2009, The Journal of pathology.
[8] Marieke E. Timmerman,et al. Smoothing waves in array CGH tumor profiles , 2009, Bioinform..
[9] Axel Benner,et al. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] S. Clifford,et al. The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials , 2009, British journal of neurosurgery.
[11] Dirk Troost,et al. Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features , 2008, PloS one.
[12] Robert Gentleman,et al. Bioconductor Case Studies , 2008 .
[13] E. Holland,et al. c-Myc and β-catenin cooperate with loss of p53 to generate multiple members of the primitive neuroectodermal tumor family in mice , 2008, Oncogene.
[14] J. Rutka,et al. The molecular genetics of medulloblastoma: an assessment of new therapeutic targets , 2008, Neurosurgical Review.
[15] Peter Lichter,et al. The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma , 2008, International journal of cancer.
[16] Renee F Wilson,et al. Systematic Review: Gene Expression Profiling Assays in Early-Stage Breast Cancer , 2008, Annals of Internal Medicine.
[17] S. Pomeroy,et al. Gain of 1q Is a Potential Univariate Negative Prognostic Marker for Survival in Medulloblastoma , 2007, Clinical Cancer Research.
[18] T. MacDonald,et al. Medulloblastoma in childhood: new biological advances , 2007, The Lancet Neurology.
[19] John Y. H. Kim,et al. Overexpressed TP73 induces apoptosis in medulloblastoma , 2007, BMC Cancer.
[20] Hidetoshi Shimodaira,et al. Pvclust: an R package for assessing the uncertainty in hierarchical clustering , 2006, Bioinform..
[21] D. Pearson,et al. High-Resolution Array-Based Comparative Genomic Hybridization of Medulloblastomas and Supratentorial Primitive Neuroectodermal Tumors , 2006, Journal of neuropathology and experimental neurology.
[22] T. Curran,et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] B. Korn,et al. Isochromosome breakpoints on 17p in medulloblastoma are flanked by different classes of DNA sequence repeats , 2006, Genes, chromosomes & cancer.
[24] J. Rutka,et al. Array CGH analysis of pediatric medulloblastomas , 2006, Genes, chromosomes & cancer.
[25] Axel Benner,et al. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Claire L Weston,et al. beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] J. Biegel,et al. Isochromosome 17q Is a Negative Prognostic Factor in Poor-Risk Childhood Medulloblastoma Patients , 2005, Clinical Cancer Research.
[28] D. Ellison,et al. Combined Histopathological and Molecular Cytogenetic Stratification of Medulloblastoma Patients , 2004, Clinical Cancer Research.
[29] S. Scherer,et al. Failure of a medulloblastoma-derived mutant of SUFU to suppress WNT signaling , 2004, Oncogene.
[30] F. Kokocinski,et al. Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. , 2004, Cancer research.
[31] C. Dang,et al. Histopathological and Molecular Prognostic Markers in Medulloblastoma: c‐myc, N‐myc, TrkC, and Anaplasia , 2004, Journal of neuropathology and experimental neurology.
[32] S. Ishii,et al. Oncogenic Activation of c-Myb Correlates with a Loss of Negative Regulation by TIF1β and Ski*[boxs] , 2004, Journal of Biological Chemistry.
[33] Gordon K Smyth,et al. Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .
[34] Rafael A Irizarry,et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.
[35] D. Ellison,et al. Classifying the medulloblastoma: insights from morphology and molecular genetics , 2002, Neuropathology and applied neurobiology.
[36] T. Poggio,et al. Prediction of central nervous system embryonal tumour outcome based on gene expression , 2002, Nature.
[37] J. Crolla,et al. Clinical and molecular stratification of disease risk in medulloblastoma , 2001, British Journal of Cancer.
[38] Nello Cristianini,et al. Support vector machine classification and validation of cancer tissue samples using microarray expression data , 2000, Bioinform..
[39] R. McLendon,et al. Characterization of chromosome 17 abnormalities in medulloblastomas , 2000, Acta Neuropathologica.
[40] J. Trojanowski,et al. TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] L. Rorke,et al. Medulloblastoma: clinical and biologic aspects. , 1999, Neuro-oncology.
[42] Tracey A. Cho,et al. Activation of neurotrophin-3 receptor TrkC induces apoptosis in medulloblastomas. , 1999, Cancer research.
[43] L. Chin,et al. Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression , 1997, nature.
[44] J. Biegel,et al. Prognostic significance of chromosome 17p deletions in childhood primitive neuroectodermal tumors (medulloblastomas) of the central nervous system. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[45] C. Metz,et al. A receiver operating characteristic partial area index for highly sensitive diagnostic tests. , 1996, Radiology.
[46] J. Biegel,et al. Isochromosome 17q demonstrated by interphase fluorescence in situ hybridization in primitive neuroectodermal tumors of the central nervous system , 1995, Genes, chromosomes & cancer.
[47] Genes, chromosomes & cancer , 1995 .
[48] S. Pomeroy,et al. Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[49] Jane Fridlyand,et al. Bioinformatics Original Paper a Comparison Study: Applying Segmentation to Array Cgh Data for Downstream Analyses , 2022 .
[50] S. Elledge,et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease , 2003, Nature Genetics.
[51] S. Pomeroy,et al. Identification of PATCHED mutations in medulloblastomas by direct sequencing. , 2000, Human mutation.
[52] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[53] A. Olshen,et al. A Faster Circular Binary Segmentation Algorithm for the Analysis of Array Cgh Data , 2022 .